Research Journal of Pharmacy and Technology
SCOPUS
  • Year: 2024
  • Volume: 17
  • Issue: 7

Andrographolide: A drug of choice for skin carcinoma

  • Author:
  • A. S Pednekar**, C Sowmya*, S. N. Mamle Desai***, P. M. M. D. Jovita****
  • Total Page Count: 7
  • Page Number: 3514 to 3520

Faculty of Pharmacy, Sriramachandra Institute of Higher Education and Research (Deemed to be University)Porur, Chennai600116

*Corresponding Author E-mail: drcsowmya@sriramachandra.edu.in

**pednekar_arti@sriramachandra.edu.in

***snm101991@gmail.com

****jovimartin4@gmail.com

Online published on 29 April, 2025.

Abstract

The skin carcinoma is predominantly observed in white population. Based upon clinical behaviour carcinoma may be classified as non-melanomatous skin carcinoma and malignant melanoma. Further cells affected non-melanomatous skin carcinoma is classified as basal cell carcinoma and squamous cell carcinoma. Andrographolide is a potent anticancer agent. It is isolated mostly from the leaves and roots of Andrographis Paniculata and chemically is a labdane diterpenoid. It is useful in the treatment of carcinoma of colon, breast, head, neck, prostate, glioblastoma and skin. Inhibiting proliferation and inducing apoptosis is the mechanism by which cancerous cells acts in treating carcinoma. 14-acetylandrographolide, one of the potent derivative of andrographolide.

Keywords

Andrographolide, Nonmelanocytic skin carcinoma, Malignant melanoma, Skin Carcinoma